Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors - Wikidata - wikimedia - TriplyDB

Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors

Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors

http://www.wikidata.org/entity/Q33864976

about

CD44 promotes multi-drug resistance by protecting P-glycoprotein from FBXO21-mediated ubiquitination Effect of maintenance immunosuppressive drugs on virus pathobiology: evidence and potential mechanisms.

P2860

Q36413446-5DE10895-C5E6-482E-9098-FDEB26E82CE5 Q38061056-602B69B9-FADD-425B-A293-A024BE898C15

P2860

Oral cyclosporin A inhibits CD4 T cell P-glycoprotein activity in HIV-infected adults initiating treatment with nucleoside reverse transcriptase inhibitors

http://www.wikidata.org/entity/Q33864976

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@ast

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@en

type

label

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@ast

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@en

prefLabel

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@ast

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@en

P1433

Q33864976-2CEAEC18-36E8-426E-A3A6-32DF0184ECF5

P1476

Q33864976-64308A9C-3D3B-4D45-A741-2A6F30B144AB

P2093

Q33864976-2EA791A0-9989-4C3A-9A63-1FC5F1B04FC6

Q33864976-3160AE31-0AA9-44AB-9D85-5F0FD709CBB1

Q33864976-34439EC1-D68B-4924-8835-08F00C9A82F1

Q33864976-76C20BF5-DB06-4B8D-B95D-B8476934D9CC

Q33864976-B5CC5782-7277-446F-B9C0-C9BE10830F85

Q33864976-BB1ECF92-E2C8-4B03-A6FD-C74215E26619

Q33864976-D1562C57-3377-44AD-A59F-72061CCB9BD0

Q33864976-E2441F26-08BF-47E2-BEB1-16F149CA532B

Q33864976-F5B402C1-224C-47CE-A471-6A43C78322ED

Q33864976-F62D80C8-B2BF-44F8-86A5-AD7FC45A729A

P2860

Q33864976-0546E95D-D9DD-4798-8229-3A9AB6CB41C2

Q33864976-06F6B8C6-13B5-4E00-B974-E3722A40752E

Q33864976-079505EF-FA5D-4647-8653-E4D8D38EDCAC

Q33864976-0B7C06E5-A319-46CB-BCE5-7F8DE6891E3F

Q33864976-0BBD11A7-D482-46EA-8872-F371A0DBA1BE

Q33864976-109F2886-49B4-408F-95E7-571799F636C0

Q33864976-14EA32D4-FBAC-46FA-911F-B2EA5AD9595B

Q33864976-17898A50-73A6-45F6-839C-4C99084D0928

Q33864976-1F8B9623-F06A-4B96-9613-091197498C26

Q33864976-2E2AF2C9-2C37-4DA1-90B7-F722D0A91BE1

P2888

Q33864976-E8BDB32A-5A6D-4FD4-8626-7F66DC472489

P304

Q33864976-338808AD-1C7F-4CED-A672-3F5527CD4B7E

P31

Q33864976-9CF3E1D3-9C48-4997-85B0-A50BAB98B405

P356

Q33864976-4A94928C-D915-4DD8-AB3A-B236C4E42A87

P433

Q33864976-67F18F8F-DA4D-42A1-B3EC-2C80F3366780

P478

Q33864976-240BF2D2-97CC-49FB-9077-F31990F700C1

P577

Q33864976-D2915C94-2E5E-42CD-96F9-9C9DEE91C03D

P5875

Q33864976-0012FA89-EB0F-4AC7-824F-183E9F170499

P6179

Q33864976-598C88FF-94F2-4750-AF01-5141B145AC76

P698

Q33864976-FC01D8A3-FFB6-49DF-81D3-437D37E6EC34

P932

Q33864976-A55CC570-C7E9-4E6E-A0B1-75CEECA77E12

P356

S00228-009-0725-5

P1433

European Journal of Clinical Pharmacology

P1476

Oral cyclosporin A inhibits CD ...... verse transcriptase inhibitors

@en

P2093

AIDS Clinical Trials Group Study A5138 Team

http://www.w3.org/2001/XMLSchema#string

Christopher Pilcher

http://www.w3.org/2001/XMLSchema#string

David W Haas

http://www.w3.org/2001/XMLSchema#string

Hernan Valdez

http://www.w3.org/2001/XMLSchema#string

Hongying Wang

http://www.w3.org/2001/XMLSchema#string

John P Donahue

http://www.w3.org/2001/XMLSchema#string

Kimberly Smith

http://www.w3.org/2001/XMLSchema#string

Laura Smeaton

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

Minya Pu

http://www.w3.org/2001/XMLSchema#string

P2860

Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues

P-glycoprotein-mediated active efflux of the anti-HIV1 nucleoside abacavir limits cellular accumulation and brain distribution

A "silent" polymorphism in the MDR1 gene changes substrate specificity

Coadministration of cyclosporine strongly enhances the oral bioavailability of docetaxel.

Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters

Full blockade of intestinal P-glycoprotein and extensive inhibition of blood-brain barrier P-glycoprotein by oral treatment of mice with PSC833

The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

Polymorphisms in human MDR1 (P-glycoprotein): recent advances and clinical relevance.

Pharmacoenhancement of protease inhibitors.

The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis.

P2888

s00228-009-0725-5

P304

1081-1088

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00228-009-0725-5

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

65

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227118379

http://www.w3.org/2001/XMLSchema#string

P6179

1006067594

http://www.w3.org/2001/XMLSchema#string

P698

19779705

http://www.w3.org/2001/XMLSchema#string

P932

2873632

http://www.w3.org/2001/XMLSchema#string